Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed Nov 8, 2021 · 10-Q · 39 days after period end · 0001104659-21-135762
| Metric | Q3 2021 | Q3 2020 |
|---|---|---|
| Revenue | $52.28M | — |
| Net Income | -$432.03K | -$137.66K |
| EPS Diluted | -$0.05 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Nov 8, 2021 · 39 d after period end
